Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
Enterprise Group, Inc. (TSX: E) (the “Company” or ”Enterprise”). Enterprise, a consolidator of energy services (including specialized equipment rental to the energy/resource sector), emphasizes technologies that mitigate, reduce, or eliminate CO2 and Greenhouse Gas emissions for small to Tier One resource clients.
Fundamental Research Corp (FRC) recently released an in-depth research report on this unique and growing company. The chart tells the tale of the positivity exacted by the trade history TYD 2022.
Here are some salient and recent information sources for new potential investors and current shareholders.
Article by StreetwiseReports
Interestingly, FRC very recently released an update following the release of Enterprise’s Q2/2022.
| Three months June 30th, 2022 | Three months June 30th, 2021 | Six months June 30th, 2022 | Six months June 30th, 2021 | ||||||||||||||||||
| Revenue | $ | 5,297,685 | $ | 3,225,543 | $ | 12,927,103 | $ | 9,084,830 | |||||||||||||
| Gross margin | $ | 1,610,188 | 30% | $ | 580,312 | 18% | $ | 5,131,973 | 40% | $ | 3,306,699 | 36% | |||||||||
| Adjusted gross margin(1)(2) | $ | 1,610,188 | 30% | $ | 120,950 | 4% | $ | 5,131,973 | 40% | $ | 2,046,821 | 23% | |||||||||
| Adjusted EBITDA(1)(2) | $ | 1,015,978 | 19% | $ | (394,835 | ) | (12)% | $ | 4,045,803 | 31% | $ | 1,070,547 | 12% | ||||||||
| Net (loss) income and comprehensive (loss) income | $ | (513,268 | ) | $ | (1,626,547 | ) | $ | 1,164,744 | $ | (1,532,910 | ) | ||||||||||
| (Loss) the income per share – Basic | $ | (0.01 | ) | $ | (0.03 | ) | $ | 0.02 | $ | (0.03 | ) | ||||||||||
| (Loss) the income per share – Diluted | $ | (0.01 | ) | $ | (0.03 | ) | $ | 0.02 | $ | (0.03 | ) |
FRC updated the report results, as its research initially hit pre-Q2.
- Q2-2022 revenue jumped 64% YoY (Q1 revenue was up 30% YoY) and was 2% higher than our estimate.
- Note that Q2 and Q3 are historically weaker quarters due to seasonality.
- Due to more substantial revenue, gross margins improved YoY (18% to 30%).
- EBITDA was up YoY from $0.14M to $1.02M and 4% higher than our estimate.
- Oil prices have pulled back from their highs in March 2022 but are still up 40% YoY.
- FRC has a positive outlook on oil prices as we are expecting a prolonged period of conflict between the West and East.
- FRC is raising its 2022 revenue and EBITDA projections.
Oil and Gas will be volatile given events in Europe and issues with green energy. Companies like Enterprise and others in its space will become more relevant as drilling increases to meet the demand that is still apparent both from a supply and technology perspective.
There’s lots more to Enterprise as a growth story, a proxy for the resource sector and a leader in cutting-edge technologies to address climate and emission issues.
Enterprise’s historical revenue (2014-2022) has been strongly correlated to oil prices. During 2014-2022, Enterprise revenue increased/decreased by 0.8% for every 1% change in oil prices.
More to come. Lots more, including the shares at CDN$0.40, are trading well below its asset value of nearly CDN$0.65
Next time we’ll look at Enterprise’s new division Evolution Power (EPP) and the massive rise in resource sector Capex spending.
EPP Teaser: EPP is the leading provider of low emission, portable power systems and associated surface infrastructure to the Energy, Resource, and Industrial sectors. The company’s highly innovative methods are delivering its client’s low emission natural gas-powered systems and micro-grid technology, allowing clients to eliminate diesel. EPP’s systems are equipped to deliver real-time emission metrics providing its clients with the assurances necessary for them to accomplish their ESG reporting and objectives. (PR August 11th)
And you have to love the chart, given the markets’ volatility of late.
10x Alerts
-
10x Alerts#molongui-disabled-link
-
10x Alerts#molongui-disabled-link
-
10x Alerts#molongui-disabled-link
All Articles
The latest
INVESTMENT: THIS AI FIRM JUST RELEASED SOME GAME-CHANGING NEWS
Alset Capital Inc. (TSXV: KSUM) : Innovative Advancements Together with Nvidia
Discover The Phillips Township Property from Golden Rapture (CSE:GLDR)
Subscribe
©2024 10xAlerts